In a new clinical trial, City of Hope is investigating a treatment for cancer patients with COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis, which is inexpensive and has few serious side effects.
A novel cancer therapy studied and developed at the Medical College of Wisconsin with promising clinical outcomes is leading to a larger phase II trial to improve on the current standard of care.
Researchers at MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and develop side effects.
A study from researchers at MD Anderson Cancer Center indicates that mutations found in cancers do not accumulate randomly, but are found in distinct patterns that vary based on the three-dimensional organization of the genome in the cell as well as the underlying factors causing the mutations.
Researchers at the University of California San Diego School of Medicine found that patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy.
The phase III CheckMate-816 trial met a primary endpoint of pathologic complete response in resectable non-small cell lung cancer.
One of the more complex tasks that I performed in my medical oncology practice was enrolling patients on a clinical trial.
Kelvin Lee was named director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Jan Kitajewski was named director of the University of Illinois Cancer Center, effective Oct. 16, 2020.
Ira Pastan, distinguished investigator at NCI, has received the Paul A. Volcker Career Achievement Medal from the Partnership for Public Service for his discovery of moxetumomab pasudotox-tdfk (Lumoxiti), which is indicated for the treatment of relapsed or refractory hairy cell leukemia.
